Your web browser is out of date.

For your security and improved experience online, please update your browser.
Update your browser

Diabetes on the Net is intended for healthcare professionals

back to main site

Back to home page

This video was originally broadcast on 13 May 2020. Please note that the speaker is not able to answer questions from attendees watching the video on-demand.

MANAGEMENT OF PEOPLE WITH COVID-19 AND DIABETES

Speaker: David Millar-Jones, GP, Cwmbran
Date of session: 13th May 2020

Download a summary of the Q&A from the broadcast.

VIRTUAL SMART UPDATE IN DIABETES PROGRAMME 2020

View the presentation delivered by Dr. David Millar-Jones as he examines the following topics:

1. The story of COVID-19

2. COVID 19 and diabetes: Examining the evidence

3. How to advise people with diabetes:

  • Tips for managing isolation
  • Emotional wellbeing
  • Sick day management
 

4. Future diabetes and chronic disease management

This independent programme has been funded by AstraZeneca. AstraZeneca has had no editorial input into, or control over the content. PCDS is responsible for the content of all materials and selection of speakers pertaining to this.

get the latest news

subscribe now

© Copyright OmniaMed Communications. All Rights Reserved

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

Confirm
* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.